"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 7 | 8 |
| 1994 | 0 | 4 | 4 |
| 1995 | 0 | 17 | 17 |
| 1996 | 0 | 11 | 11 |
| 1997 | 0 | 11 | 11 |
| 1998 | 1 | 8 | 9 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 18 | 18 |
| 2001 | 0 | 8 | 8 |
| 2002 | 0 | 11 | 11 |
| 2003 | 0 | 14 | 14 |
| 2004 | 0 | 16 | 16 |
| 2005 | 1 | 13 | 14 |
| 2006 | 0 | 12 | 12 |
| 2007 | 1 | 15 | 16 |
| 2008 | 0 | 20 | 20 |
| 2009 | 0 | 17 | 17 |
| 2010 | 0 | 12 | 12 |
| 2011 | 1 | 22 | 23 |
| 2012 | 1 | 15 | 16 |
| 2013 | 0 | 16 | 16 |
| 2014 | 0 | 18 | 18 |
| 2015 | 0 | 16 | 16 |
| 2016 | 0 | 14 | 14 |
| 2017 | 0 | 11 | 11 |
| 2018 | 1 | 18 | 19 |
| 2019 | 2 | 17 | 19 |
| 2020 | 3 | 16 | 19 |
| 2021 | 0 | 13 | 13 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204.
-
The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncol Pract. 2023 02; 19(2):74-85.
-
High early death rates, treatment resistance, and short survival of?Black adolescents and young adults with AML. Blood Adv. 2022 10 11; 6(19):5570-5581.
-
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022 10 03; 28(10):1549-1554.
-
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211.
-
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-16.
-
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8.
-
Higher vs Standard Adalimumab Induction Dosing Regimens and?Two Maintenance Strategies: Randomized SERENE CD Trial?Results. Gastroenterology. 2022 06; 162(7):1876-1890.
-
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 01 11; 114(1):160-164.
-
FZD10-targeted a-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model. Cancer Sci. 2022 Feb; 113(2):721-732.